For example, in a VEGF-A/VEGFR blockade-resistant syngeneic pancreatic cancer mouse model, concurrent mAb targeting of Ang2 suppressed re-vascularisation and tumour progression [93]. This evidence concerns the gene VEGFA and neoplasm.